This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2023 Dec 20;190(1):e2.

doi: 10.1093/bjd/ljad468.

Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years

No authors listed

PMID: 38124526
DOI: 10.1093/bjd/ljad468

Editorial

Nemolizumab reduces itch and improves other signs of atopic dermatitis in children aged 6-12 years

No authors listed. Br J Dermatol. 2023.

. 2023 Dec 20;190(1):e2.

doi: 10.1093/bjd/ljad468.

PMID: 38124526
DOI: 10.1093/bjd/ljad468

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of nemolizumab in paediatric patients aged 6-12 years with atopic dermatitis with moderate-to-severe pruritus: results from a phase III, randomized, double-blind, placebo-controlled, multicentre study.
Igarashi A, Katsunuma T, Matsumura T, Komazaki H; Nemolizumab-JP04 Study Group. Igarashi A, et al. Br J Dermatol. 2023 Dec 20;190(1):20-28. doi: 10.1093/bjd/ljad268. Br J Dermatol. 2023. PMID: 37522351 Clinical Trial.

References

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Silverchair Information Systems